157 related articles for article (PubMed ID: 34022116)
1. Circulating tumor DNA as a predictive marker for occult metastases in pancreatic cancer patients with radiographically non-metastatic disease.
Hata T; Mizuma M; Iseki M; Takadate T; Ishida M; Nakagawa K; Hayashi H; Morikawa T; Motoi F; Unno M
J Hepatobiliary Pancreat Sci; 2021 Aug; 28(8):648-658. PubMed ID: 34022116
[TBL] [Abstract][Full Text] [Related]
2. Circulating Nucleic Acids Are Associated With Outcomes of Patients With Pancreatic Cancer.
Bernard V; Kim DU; San Lucas FA; Castillo J; Allenson K; Mulu FC; Stephens BM; Huang J; Semaan A; Guerrero PA; Kamyabi N; Zhao J; Hurd MW; Koay EJ; Taniguchi CM; Herman JM; Javle M; Wolff R; Katz M; Varadhachary G; Maitra A; Alvarez HA
Gastroenterology; 2019 Jan; 156(1):108-118.e4. PubMed ID: 30240661
[TBL] [Abstract][Full Text] [Related]
3. Longitudinal monitoring of KRAS-mutated circulating tumor DNA enables the prediction of prognosis and therapeutic responses in patients with pancreatic cancer.
Watanabe F; Suzuki K; Tamaki S; Abe I; Endo Y; Takayama Y; Ishikawa H; Kakizawa N; Saito M; Futsuhara K; Noda H; Konishi F; Rikiyama T
PLoS One; 2019; 14(12):e0227366. PubMed ID: 31891652
[TBL] [Abstract][Full Text] [Related]
4. Analysis of ctDNA to predict prognosis and monitor treatment responses in metastatic pancreatic cancer patients.
Cheng H; Liu C; Jiang J; Luo G; Lu Y; Jin K; Guo M; Zhang Z; Xu J; Liu L; Ni Q; Yu X
Int J Cancer; 2017 May; 140(10):2344-2350. PubMed ID: 28205231
[TBL] [Abstract][Full Text] [Related]
5. Mutant
Perets R; Greenberg O; Shentzer T; Semenisty V; Epelbaum R; Bick T; Sarji S; Ben-Izhak O; Sabo E; Hershkovitz D
Oncologist; 2018 May; 23(5):566-572. PubMed ID: 29371474
[TBL] [Abstract][Full Text] [Related]
6. Clinical correlates of blood-derived circulating tumor DNA in pancreatic cancer.
Patel H; Okamura R; Fanta P; Patel C; Lanman RB; Raymond VM; Kato S; Kurzrock R
J Hematol Oncol; 2019 Dec; 12(1):130. PubMed ID: 31801585
[TBL] [Abstract][Full Text] [Related]
7. Highly Sensitive Circulating Tumor DNA Assay Aids Clinical Management of Radiographically Occult Isolated Peritoneal Metastases in Patients With GI Cancer.
Singh H; Klempner SJ; Melnitchouk N; Chander DP; Negrea OG; Patel AK; Schlechter BL; Rubinson DA; Huffman BM; Nambiar C; Remland J; Andrews E; Leahy ME; Brais LK; Enzinger PC; Mamon HJ; Giannakis M; Meyerhardt JA; Ng K; Perez KJ; Aguirre AJ; Clark JW; Cleary JM; Wolpin BM
JCO Precis Oncol; 2023 Jun; 7():e2200572. PubMed ID: 37343200
[TBL] [Abstract][Full Text] [Related]
8. Prognostic impact of postoperative circulating tumor DNA as a molecular minimal residual disease marker in patients with pancreatic cancer undergoing surgical resection.
Hata T; Mizuma M; Motoi F; Ohtsuka H; Nakagawa K; Morikawa T; Unno M
J Hepatobiliary Pancreat Sci; 2023 Jun; 30(6):815-824. PubMed ID: 36408698
[TBL] [Abstract][Full Text] [Related]
9. Preoperative Circulating Tumor DNA in Patients with Peritoneal Carcinomatosis is an Independent Predictor of Progression-Free Survival.
Baumgartner JM; Raymond VM; Lanman RB; Tran L; Kelly KJ; Lowy AM; Kurzrock R
Ann Surg Oncol; 2018 Aug; 25(8):2400-2408. PubMed ID: 29948422
[TBL] [Abstract][Full Text] [Related]
10. Prognostic value of circulating tumour DNA in metastatic pancreatic cancer patients: post-hoc analyses of two clinical trials.
Pietrasz D; Wang-Renault S; Taieb J; Dahan L; Postel M; Durand-Labrunie J; Le Malicot K; Mulot C; Rinaldi Y; Phelip JM; Doat S; Blons H; de Reynies A; Bachet JB; Taly V; Laurent-Puig P
Br J Cancer; 2022 Feb; 126(3):440-448. PubMed ID: 34811505
[TBL] [Abstract][Full Text] [Related]
11. Plasma Circulating Tumor DNA in Pancreatic Cancer Patients Is a Prognostic Marker.
Pietrasz D; Pécuchet N; Garlan F; Didelot A; Dubreuil O; Doat S; Imbert-Bismut F; Karoui M; Vaillant JC; Taly V; Laurent-Puig P; Bachet JB
Clin Cancer Res; 2017 Jan; 23(1):116-123. PubMed ID: 27993964
[TBL] [Abstract][Full Text] [Related]
12. Circulating tumor DNA correlates with tumor burden and predicts outcome in pancreatic cancer irrespective of tumor stage.
Kirchweger P; Kupferthaler A; Burghofer J; Webersinke G; Jukic E; Schwendinger S; Weitzendorfer M; Petzer A; Függer R; Rumpold H; Wundsam H
Eur J Surg Oncol; 2022 May; 48(5):1046-1053. PubMed ID: 34876329
[TBL] [Abstract][Full Text] [Related]
13. Circulating tumor DNA quantity is related to tumor volume and both predict survival in metastatic pancreatic ductal adenocarcinoma.
Strijker M; Soer EC; de Pastena M; Creemers A; Balduzzi A; Beagan JJ; Busch OR; van Delden OM; Halfwerk H; van Hooft JE; van Lienden KP; Marchegiani G; Meijer SL; van Noesel CJ; Reinten RJ; Roos E; Schokker S; Verheij J; van de Vijver MJ; Waasdorp C; Wilmink JW; Ylstra B; Besselink MG; Bijlsma MF; Dijk F; van Laarhoven HW
Int J Cancer; 2020 Mar; 146(5):1445-1456. PubMed ID: 31340061
[TBL] [Abstract][Full Text] [Related]
14. MicroRNA-593-3p Expression in Peritoneal Lavage Fluid as a Prognostic Marker for Pancreatic Cancer Patients Undergoing Staging Laparoscopy.
Hata T; Mizuma M; Masuda K; Chiba K; Ishida M; Ohtsuka H; Nakagawa K; Morikawa T; Kamei T; Unno M
Ann Surg Oncol; 2021 Apr; 28(4):2235-2245. PubMed ID: 33393045
[TBL] [Abstract][Full Text] [Related]
15. Circulating Tumor DNA Is an Accurate Diagnostic Tool and Strong Prognostic Marker in Pancreatic Cancer.
Sellahewa R; Moghaddam SM; Lundy J; Jenkins BJ; Croagh D
Pancreas; 2023 Mar; 52(3):e188-e195. PubMed ID: 37751379
[TBL] [Abstract][Full Text] [Related]
16. Impact of Tumor-Derived DNA Testing in Peritoneal Lavage of Pancreatic Cancer Patients with and Without Occult Intra-Abdominal Metastases.
Chiba K; Hata T; Mizuma M; Masuda K; Aoki S; Takadate T; Kawaguchi K; Nakagawa K; Morikawa T; Motoi F; Furukawa T; Unno M
Ann Surg Oncol; 2022 Apr; 29(4):2685-2697. PubMed ID: 34739641
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of circulating tumor DNA as a biomarker in pancreatic cancer with liver metastasis.
Uesato Y; Sasahira N; Ozaka M; Sasaki T; Takatsuki M; Zembutsu H
PLoS One; 2020; 15(7):e0235623. PubMed ID: 32614932
[TBL] [Abstract][Full Text] [Related]
18. Prognostic Utility of Pre- and Postoperative Circulating Tumor DNA Liquid Biopsies in Patients with Peritoneal Metastases.
Baumgartner JM; Riviere P; Lanman RB; Kelly KJ; Veerapong J; Lowy AM; Kurzrock R
Ann Surg Oncol; 2020 Sep; 27(9):3259-3267. PubMed ID: 32767050
[TBL] [Abstract][Full Text] [Related]
19. Prognostic value of circulating tumor DNA in pancreatic cancer: a systematic review and meta-analysis.
Fang Z; Meng Q; Zhang B; Shi S; Liu J; Liang C; Hua J; Yu X; Xu J; Wang W
Aging (Albany NY); 2020 Dec; 13(2):2031-2048. PubMed ID: 33318293
[TBL] [Abstract][Full Text] [Related]
20. Circulating tumor DNA as a prognostic marker in high-risk endometrial cancer.
Feng W; Jia N; Jiao H; Chen J; Chen Y; Zhang Y; Zhu M; Zhu C; Shen L; Long W
J Transl Med; 2021 Feb; 19(1):51. PubMed ID: 33536036
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
